DL-3-n-butylphthalide inhibits platelet activation via inhibition of cPLA2-mediated TXA2 synthesis and phosphodiesterase.

In conclusion, NBP significantly inhibits human platelet activation via inhibition of cPLA2-mediated TXA2 synthesis and PDE, and may be effective as an antiplatelet drug to treat other arterial thrombotic diseases. PMID: 25734213 [PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/25734213?dopt=Abstract

Source: Platelets - February 14, 2016 Category: Hematology Tags: Platelets Source Type: research